Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EBT (2016 - 2025)

Historic EBT for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $34.3 million.

  • Amicus Therapeutics' EBT rose 40514.37% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 10728.9%. This contributed to the annual value of -$28.8 million for FY2024, which is 8084.22% up from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' EBT is $34.3 million, which was up 40514.37% from -$19.2 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year EBT high stood at $34.3 million for Q3 2025, and its period low was -$81.5 million during Q1 2022.
  • Over the past 5 years, Amicus Therapeutics' median EBT value was -$40.5 million (recorded in 2023), while the average stood at -$35.0 million.
  • The largest annual percentage gain for Amicus Therapeutics' EBT in the last 5 years was 40514.37% (2025), contrasted with its biggest fall of 1786018.52% (2025).
  • Over the past 5 years, Amicus Therapeutics' EBT (Quarter) stood at -$80.3 million in 2021, then rose by 12.72% to -$70.1 million in 2022, then soared by 54.82% to -$31.7 million in 2023, then skyrocketed by 125.06% to $7.9 million in 2024, then skyrocketed by 331.99% to $34.3 million in 2025.
  • Its last three reported values are $34.3 million in Q3 2025, -$19.2 million for Q2 2025, and -$18.0 million during Q1 2025.